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Abstract
Objective: To investigate whether the elevated liver enzymes gamma-glutamyltransferase (GGT), glutamate-pyruvate
transaminase (GPT), glutamate-oxalacetate transaminase (GOT) and alkaline phosphatase (AP) and non-alcoholic fatty liver
disease (NAFLD) respectively are independently associated with pre-diabetic states, namely impaired fasting glucose (IFG)
and impaired glucose tolerance (IGT) or known and newly diagnosed diabetes (NDD), in men and women from the general
German population.
Methods: The study was based on 3009 subjects (1556 females, 1453 males) aged 32 to 81 years who participated in the
KORA-F4-Study in 2006/2008 in Augsburg, Southern Germany. All non-diabetic participants underwent an oral glucose
tolerance test to assess disturbances in glucose metabolism. NAFLD was estimated by liver enzyme concentrations and the
Bedogni Fatty Liver Index (FLI).
Results: 229 participants (7.6%) reported known diabetes, 106 had NDD (3.5%), 107 (3.6%) had IFG, 309 (10.3%) had IGT, 69
(2.3%) were affected with both metabolic disorders (IFG/IGT) and 74 (2.5%) could not be classified. GGT and GPT were
significantly elevated in persons with pre-diabetes and diabetes (GGT in diabetic persons OR=1.76, [1.47–2.09], in IFG
OR=1.79 [1.50–2.13], GPT in diabetic persons OR=1.51, [1.30–1.74], in NDD OR=1.77 [1.52–2.06]), GOT and AP only
inconsistently in some pre-diabetes groups. The effects were sharpened in models using an increase of two or three out of
three enzymes as an estimate of fatty liver and especially in models using the FLI. Overall frequency of NAFLD applying the
index was 39.8% (women: 27.3% and men: 53.2%). In participants with fatty liver disease, the OR for NDD adjusted for sex
and age was 8.48 [5.13–14.00], 6.70 [3.74–12.01] for combined IFG and IGT and 4.78 [3.47–6.59] for known diabetes
respectively.
Conclusions: Elevated GGT and GPT–values as well as estimates of fatty liver disease are significantly associated with pre-
diabetes and diabetes and thus very useful first indicators of a disturbed glucose metabolism.
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Introduction
First described by Ludwig in 1980 [1], non-alcoholic fatty liver
disease (NAFLD) is believed to be one of the most common causes
of chronic liver disease in the Western world today. The
prevalence is likely to parallel the increasing prevalence of
diabetes, obesity, and other components of the metabolic
syndrome and varies remarkably depending on the population
studied and the diagnostic criteria used. Recent assessments,
summarized by Bellentani and Marino, amount from about 3–
30% in population based samples to 70–90% in obese patients eg.
from bariatric surgeries. About 30% of all adult Americans, 25%
of adult Italians and 14% and 15% Chinese and Japanese adults
respectively are affected [2].
The clinicopathologic syndrome of NAFLD encompassing a
spectrum of conditions ranging from benign accumulation of fat in
the liver to inflammatory steatohepatitis (NASH), fibrosis and
cirrhosis, has been characterized in detail [3–6].
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NAFLD or elevated liver enzymes is a frequent observation [7–10]
and the role of insulin resistance has been reviewed [11], few
studies with selected (clinical) populations have so far described the
association between liver enzymes as surrogate measurements of
fatty liver disease and ‘‘pre-diabetes’’ [12–16].
Thus, the specific objective of the present article was to
investigate the association between liver enzymes, fatty liver and
type 2 diabetes mellitus (known and newly detected) as well as
impaired glucose tolerance (IFG, impaired fasting glucose, IGT,
impaired glucose tolerance and the combination of IFG and IGT)
in the KORA (Cooperative Health Research in the Region of
Augsburg) F4 study, including men and women from the general
German population. The KORA study consists of an extensively
phenotyped, population based sample of men and women with a
wide age range, oral glucose tolerance tests (OGTT) and multiple
clinical measurements and is therefore optimally applicative for
confounder controlled analyses of associations concerning diabetes
and other chronic diseases.
We applied the Fatty Liver Index (FLI) by Bedogni et al. (2006)
[17] which was developed using ultrasound, is easy to adopt in
clinical practice, and has independently been tested for its
predictive ability concerning incident diabetes in a French study
[18] and its association with insulin resistance in the Italian RISC
Study [19].
Methods
Ethics statement
The investigations were carried out in accordance with the
Declaration of Helsinki, including written informed consent of all
participants. All study methods were approved by the Ethics
committee of the ‘‘Bayerische Landesa ¨rztekammer’’ Munich.
The KORA F4 study
The KORA F4 study is a follow-up of the KORA S4 study, a
population-based health survey conducted in the city of Augsburg
and two surrounding counties between 1999 and 2001. A total
sample of 6640 subjects was drawn from the target population
consisting of all German residents of the region aged 25 to 74
years.
Of all 4261 participants of the S4 baseline study, 3080 also
participated in the 7-year follow-up F4 study. Persons were
considered ineligible for F4 if they had died in the meantime
(N=176, 4%), lived outside the study region or were completely
lost to follow-up (N=206, 5%), or had demanded deletion of their
address data (N=12, 0.2%). Of the remaining 3867 eligible
persons, 174 could not be contacted, 218 were unable to come
because they were too ill or had no time, and 395 were not willing
to participate in this follow-up, giving a response rate of 79.6%.
After exclusion of participants with missing data in any of the
variables used in our analyses (N=71), 3009 subjects (1556
females (51.7%) and 1453 males) remained. Thus, all models are
based on complete case analyses.
Data collection
Information on socio-demographic variables, smoking habits,
physical activity, medication use, alcohol consumption and
household characteristics were gathered by trained medical staff
during a standardized interview. Educational attainment was
estimated by the number of school years completed by the
participant. The assessment of alcohol intake (grams per day) was
based on weekday and weekend consumption of beer, wine and
spirits and study participants provided information on their
smoking behaviour (never, past, current). Furthermore, they
underwent an extensive standardized medical examination
including the collection of blood samples. All measurement
procedures were described in detail elsewhere [20]. Waist and
hip circumferences were measured with a measurement tape in
front of a whole body mirror: waist midway between the lowest rib
and the iliac crest and hip at the greatest girth at the level of the
buttocks, between the iliac crest and the crotch. Body mass index
(BMI) was calculated as weight in kilograms divided by height in
square metres. Actual hypertension was defined as blood pressure
values $140/90 mmHg and/or use of antihypertensive medica-
tion given that the subjects were aware of being hypertensive.
Individuals who participated in leisure time physical training
during summer or winter for at least one hour per week were
classified as being physically active.
Men who consumed more than 40 g (N=412) and women who
consumed more than 20 g alcohol per day (N=290) or reported
past abuse of alcohol within the last 5 years were regarded as at-
risk alcohol drinkers and excluded from some of the models in
order to rule out alcoholic fatty liver disease.
Fatty liver disease was defined using three different approaches:
Definition A: Increase of at least two out of the three enzymes
GGT (gamma-glutamyltransferase), GPT (glutamate-pyruvate
transaminase) and GOT (glutamate-oxalacetate transaminase)
above the upper gender-specific medical reference values, which
were taken from Roche/Hitachi cobasH enzyme laboratory
manuals (2007) which included consensus values according to
Thomas et al. (2005) [21] (GGT in men 1.0 mkat/l, in women
0.67 mkat/l, GPT and GOT in men 0.83 mkat/l, in women
0.58 mkat/l).
Definition B: Increase of at least two out of the three enzymes
GGT, GPT and GOT in the upper population quartile of the
enzyme distribution (GGT in men 0.89 mkat/l, in women
0.50 mkat/l, GPT in men 0.60 mkat/l, in women 0.39 mkat/l
and GOT in men 0.53 mkat/l, in women 0.44 mkat/l). This
established cutpoint was chosen in order to be able to compare our
results with similar studies.
Definition C: Calculation of the Fatty Liver-Index (FLI)
according to Bedogni, 2006 [17]:
FLI~ etothepowerof 0:953 log triglycerides ðÞ ð z0:139 BMI
z0:718   log GGT ðÞ z0:053   waist{15:745Þ= 1ze to the ð
power of 0:953   log triglycerides ðÞ z0:139   BMIz0:718
 log GGT ðÞ z0:053   waist{15:745Þ 100
The FLI varies between 0 and 100. The score 0–29 rules out fatty
liver disease and 30–59 is defined as unclear. We combined these
two groups. A score of greater or equal 60 points was considered as
ruling in fatty liver disease. In the original study, this cutpoint had
a sensitivity of 61% and a specificity of 86% to correctly discern
patients with and without NAFLD.
OGTT-measurement to detect impaired glucose
metabolism
Previously diagnosed diabetes was defined as validated physi-
cian diagnosis or current intake of anti-diabetic agents. After an
overnight fast of at least 8 hours, all non-diabetic participants
underwent a standard 75-g oral glucose tolerance test (OGTT)
[20]. Blood was collected without stasis, refrigerated to 4–8uC and
shipped on refrigerant packaging within 4 to 6 hours to the
laboratory. Newly diagnosed diabetes (NDD), IFG, IGT, and
normal glucose tolerance (NGT) were defined according to the
I-M. Ru ¨ckert et al.: Fatty Liver and Pre-Diabetes
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challenge glucose values [22]. Thus, a participant had NGT if the
fasting glucose value was ,110 mg/dl and the 2 h-value
,140 mg/dl. NDD was diagnosed, if fasting glucose was
.125 mg/dl and post challenge glucose $200 mg/dl. IGT was
defined as having a fasting level of ,126 mg/dl and a 2 h post
glucose load of between 140 and 200 mg/dl and IFG as having a
fasting level of between 110 and 125 mg/dl and a 2 h
measurement of ,140 mg/dl.
We used the original IFG criteria (110 to 125 mg/dl or 6.1 to
6.9 mmol/l respectively) for the present analysis, as recommended
by the European Diabetes Epidemiology Group [23]. The pre-
diabetic state was defined as having either IGT, IFG or both IGT
and IFG. Participants were classified with unknown glucose status,
if they had given inconsistent information about being diabetic or
if their OGT test could not be conducted because of contraindi-
cations like pregnancy or no previous fasting period or could not
be completed correctly (because of nausea, vomiting etc.).
Clinical chemical measurements
A fasting venous blood sample was obtained from all study
participants while sitting. Blood glucose was analysed using a
hexokinase method (Gluco-quant, Roche Diagnostics, Mannheim,
Germany). Glycated hemoglobin A1c (HbA1c)-values were
assessed with a turbidimetric immunological assay (Tina-quant,
Roche Diagnostics) and plasma C-reactive protein (CRP)
concentrations were measured using a latex enhanced nephelo-
metric assay run on a BN II analyser (Dade Behring, Marburg,
Germany).
The liver enzymes GGT, GOT, GPT and AP (alkaline
phosphatase) were analyzed according to the recommendations
of the International Federation of Clinical Chemistry (IFCC) from
1983 (confirmed and extended in 2002) [21,24–29], including
optimization of substrate concentrations, employment of NaOH,
glycylglydine buffer and sample start. Pyridoxal phosphate was
applied in the assessment of GOT and GPT. Total cholesterol was
measured with the CHOD-PAP method using a CHOL Flex
device (Dade Behring), high-density lipoprotein (HDL-) cholesterol
was also determined using the CHOD-PAP method but after
selective release of HDL cholesterol on an AHDL Flex device
(Dade Behring). Triglycerides were measured in an enzymatic
colour test with the GPO-PAP method on a TGL Flex (Dade
Behring) and serum uric acid was determined on an URCA Flex
(Dade Behring) also applying an enzymatic colour test and the
uricase method.
Statistical Analyses
Continuous variables are given with medians and interquartile
ranges because of skewed distributions. Between-group bivariable
comparisons were performed with the Mann-Whitney-Wilcoxon
test (continuous variables) and multinomial unadjusted logistic
regression (categorical variables) using the NGT-group as the
reference. Variance inflation analysis revealed no collinearity
factors greater than 5, but the Spearman’s rho coefficients for
GGT vs. GPT, GOT vs. GPT and TC/HDL-cholesterol ratio vs.
triglycerides were greater than 0.5.
Odds ratios (OR) are given per one SD increment in enzyme
concentration, calculated from the subpopulation used in the
respective model. Two multinomial models using the SAS PROC
LOGISTIC procedure were created for each liver enzyme and the
three fatty liver concepts respectively, one only adjusted for sex
and age, the other for all relevant co-variables. The covariables
used included age (years), sex (male/female), education (years),
BMI (kg/m2), hypertension ($140/90 or taking medication, see
definition above), TC/HDL-cholesterol ratio (no unit), uric acid
(mmol/l), CRP (mg/l), alcohol intake/past abuse (.20 g/day in
females, .40 g/day in males, see definition above), smoking status
(non-smoker/current or ex-smoker), and physical activity (active/
inactive).
BMI was used as a categorical variable for BMI effect
modification analyses. To categorize BMI we used the WHO
international classification (1995) [30].
Moreover, sensitivity analyses were done by excluding all study
participants with enzyme values above recent medical reference
values (N=711), excluding participants with alcohol intake .20
(females) or 40 g/day (males) or past abuse (N=702), or
participants using prescription medication (N=2342) respectively.
Interaction of liver enzymes/fatty liver and sex was tested by
including interaction terms (enzyme*sex or fatty liver*sex) together
with main factors in multinomial logistic models. Goodness-of-fit
was estimated using Pearson tests, Akaike’s information criterion
(AIC) and Pseudo-R-Square.
A value of p,0.05 was considered statistically significant. All
analyses were performed with SAS software version 9.1 (SAS
Institute Inc., Cary, NC, USA.).
Results
Study characteristics
In total 229 participants (7.6%, 9.3% of men and 6.0% of
women) reported known diabetes, 106 had NDD (4.2% of men,
2.9% of women), 107 (3.6%) had IFG, 309 (10.3%) had IGT, 69
(2.3%) were affected with both metabolic disorders (IFG/IGT)
and 74 (2.5%) could not be classified. This last class mostly
resembled the NGT group (2115, 70.3%) in our models – thus
both could probably have been considered as one, but we chose to
look at them separately.
Table 1 shows study characteristics stratified for glucose
subgroup. Most important, GGT and GPT were significantly
increased in all pre-diabetes and the diabetes subgroup compared
to persons with NGT. GOT was not significantly increased in
persons with known diabetes and unknown status, but all other
groups. A significant elevation of AP values was observed in
persons with IFG, IGT, NDD and known diabetes, but not in the
group of participants who had IFG/IGT and the group with
unknown glucose tolerance status.
Other study characteristics also varied according to glucose
subgroup: participants affected with glucose disturbances were
significantly older than the healthy reference, males were more
often affected, a significantly greater number of participants with
less than 10 years education had IGT, NDD or known diabetes.
BMI, waist, hip circumference and hypertension were markedly
increased in all pre-/diabetes subgroups. Total cholesterol was
higher in pre-diabetic than normoglycemic individuals and lower
in patients with diabetes. HDL was decreased in all subgroups
compared to the reference group. There was a clear increase in
triglycerides, CRP, HbA1c and uric acid values in persons with
glucose disturbances in comparison to persons with NGT.
Alcohol intake was lower in participants with known diabetes and
otherwise not significantly different from the reference group.
Frequency of current or ex-smoking was lower in IFG, but beyond
that no association with diabetes or pre-diabetes could be detected.
Finally, affected participants were significantly less physically active
during their leisure time, especially persons with known diabetes.
Single enzyme models
Results of age and sex as well as multivariable adjusted models
with one liver enzyme as the main influencing factor are presented
I-M. Ru ¨ckert et al.: Fatty Liver and Pre-Diabetes
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N=3009 NGT IFG-NGT NFG-IGT IFG/IGT NDD Known Diabetes Unknown
(n=2115) (n=107) (n=309) (n=69) (n=106) (n=229) (n=74)
GGT 0.39 0.60 0.51 0.56 0.70 0.57 0.41
(mkat/l) (0.35) (0.74) (0.49) (0.50) (0.52) (0.53) (0.54)
,.0001 ,.0001 ,.0001 ,.0001 ,.0001 0.1372
GOT 0.40 0.46 0.44 0.44 0.46 0.42 0.40
(mkat/l) (0.14) (0.16) (0.17) (0.14) (0.22) (0.15) (0.13)
,.0001 ,.0001 0.0002 ,.0001 0.0873 0.7903
GPT 0.34 0.45 0.40 0.44 0.47 0.38 0.33
(mkat/l) (0.22) (0.27) (0.26) (0.21) (0.37) (0.26) (0.24)
,.0001 ,.0001 ,.0001 ,.0001 0.0006 0.6530
AP 1.07 1.21 1.17 1.17 1.23 1.15 1.11
(mkat/l) (0.42) (0.51) (0.39) (0.40) (0.31) (0.44) (0.38)
,.0001 ,.0001 0.0864 ,.0001 0.0005 0.6459
FLI 34.2 77.9 67.0 82.2 83.1 80.0 43.7
(51.6) (35.4) (43.1) (31.8) (25.5) (38.7) (56.9)
,.0001 ,.0001 ,.0001 ,.0001 ,.0001 0.0229
Age 52.0 62.0 65.0 65.0 65.0 69.0 53.5
(years) (21.0) (17.0) (17.0) (10.0) (18.0) (11.0) (28.0)
,.0001 ,.0001 ,.0001 ,.0001 ,.0001 0.0818
Female 54.5 33.6 53.7 39.1 43.0 41.1 47.3
(%) ,.0001 0.7936 0.0129 0.0159 0.0001 0.2220
Education 40.4 49.5 55.3 43.5 54.7 64.6 48.7
(,=10 years, %) 0.0614 ,.0001 0.6059 ,.0001 ,.0001 0.1563
Living alone 24.2 23.4 24.9 29.0 27.4 25.8 27.0
(%) 0.8424 0.7855 0.3639 0.4613 0.6024 0.5787
BMI 26.0 29.1 29.3 30.9 30.4 30.6 26.3
(kg/m2) (5.3) (5.2) (5.8) (6.4) (5.1) (7.1) (5.9)
,.0001 ,.0001 ,.0001 ,.0001 ,.0001 0.3230
Waist
cirumference
90.1 102.2 98.7 104.1 103.5 104.2 92.3
(cm) (17.5) (14.0) (15.4) (19.7) (15.6) (16.4) (16.7)
,.0001 ,.0001 ,.0001 ,.0001 ,.0001 0.0156
Hip
circumference
104.0 109.1 108.3 108.7 109.5 109.7 103.4
(cm) (9.9) (11.2) (11.8) (11.4) (9.7) (13.4) (10.9)
,.0001 ,.0001 ,.0001 ,.0001 ,.0001 0.5824
Waist-Hip Ratio 0.86 0.94 0.91 0.95 0.94 0.96 0.88
(0.12) (0.10) (0.12) (0.08) (0.10) (0.10) (0.14)
,.0001 ,.0001 ,.0001 ,.0001 ,.0001 0.0083
Systolic blood pressure 117.5 128.0 125.0 134.5 132.0 131.0 121.3
(mm HG) (23.0) (20.5) (24.5) (19.0) (23.5) (24.0) (24.0)
,.0001 ,.0001 ,.0001 ,.0001 ,.0001 0.0414
Diastolic blood pressure 74.0 77.0 74.5 81.0 76.0 74.0 75.3
(mm HG) (13.0) (14.5) (13.0) (10.5) (13.0) (13.5) (13.5)
0.0094 0.1232 ,.0001 0.0162 0.6681 0.8405
Current hypertension 27.5 53.3 54.7 69.6 77.4 79.5 39.2
(%) ,.0001 ,.0001 ,.0001 ,.0001 ,.0001 0.0288
Total cholesterol 213.0 221.0 225.0 222.0 214.0 198.0 220.5
(mg/dL) (50.0) (47.0) (56.0) (50.0) (44.0) (53.0) (52.0)
0.0120 ,.0001 0.0117 0.3936 ,.0001 0.2387
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the same extent (e.g. IFG: OR=1.79, 95% CI: 1.50–2.13) in all
subgroups. The effect remained significant after including multiple
confounding variables in IFG, IGT, NDD, diabetes and the group
with unknown status with a maintained tendency in the IFG/IGT
group.
ORs were smaller, but also significant for GOT in IFG, IGT
and NDD (OR for NDD: 1.40, 95% CI: 1.22–1.61). The other
groups pointed in the same direction. Multivariable adjustment led
to smaller though still significant effects. Similarly to GGT, in age
and sex adjusted analyses GPT was significantly related to all
glucose subgroups, except the group with unknown status (e.g. OR
for IFG-IGT: 1.62, 95% CI: 1.34–1.97, OR for NDD: 1.77, 95%
CI: 1.52–2.06). Only the group with IFG/IGT lost some
significance after multivariable control (OR=1.32, 95% CI:
1.05–1.67). Finally, AP showed least significant and smallest
associations and only IFG remained significant in the extended
model. The p-values for the interactions of GOT (p=0.0159) and
GPT (p=0.0009) with sex were only statistically significant in the
subgroup of known diabetes. GGT had some significant
interaction with sex in the group with unknown status
(p=0.0401). If interaction models were adjusted for age, all
enzyme-sex interactions became non-significant.
Data are not shown for further modified models stratified for sex
and excluding participants with liver values above reference limits
that were calculated to check sensitivity since the results were
found to be quite stable.
All Pseudo-R-Square values were satisfactory between 0.2 and
0.4, Pearson tests and AICs confirmed appropriate goodness-of-fit
of all models.
N=3009 NGT IFG-NGT NFG-IGT IFG/IGT NDD Known Diabetes Unknown
(n=2115) (n=107) (n=309) (n=69) (n=106) (n=229) (n=74)
HDL cholesterol 56.0 49.0 53.0 47.0 45.5 48.0 53.0
(mg/dL) (20.0) (18.0) (19.0) (17.0) (17.0) (15.0) (25.0)
,.0001 0.0013 ,.0001 ,.0001 ,.0001 0.0992
TC/HDL ratio 3.8 4.5 4.2 4.7 4.6 4.2 4.1
(1.5) (1.6) (1.5) (1.8) (1.6) (1.4) (1.4)
,.0001 ,.0001 ,.0001 ,.0001 ,.0001 0.0327
TC/HDL ratio
$5( % )
16.5 31.8 24.9 43.5 36.8 22.7 23.0
,.0001 0.0003 ,.0001 ,.0001 0.0185 0.1451
Triglycerides 94.0 129.0 119.0 171.0 147.0 137.0 111.0
(mg/dL) (69.0) (86.0) (78.0) (120.0) (124.0) (94.0) (78.0)
,.0001 ,.0001 ,.0001 ,.0001 ,.0001 0.0094
HbA1c 5.4 5.7 5.6 5.8 6.1 6.7 5.4
(%) (0.5) (0.4) (0.5) (0.5) (0.8) (1.2) (0.5)
,.0001 ,.0001 ,.0001 ,.0001 ,.0001 0.4694
Uric acid 4.9 6.1 5.5 6.0 5.8 6.0 5.2
(mmol/l) (1.8) (2.2) (1.9) (1.6) (1.7) (2.1) (2.2)
,.0001 ,.0001 ,.0001 ,.0001 ,.0001 0.2394
CRP 1.0 1.5 1.7 2.4 2.9 1.9 1.2
(mg/l) (1.6) (2.9) (3.1) (2.8) (4.4) (2.8) (2.5)
,.0001 ,.0001 ,.0001 ,.0001 ,.0001 0.0573
Alcohol intake 5.7 9.5 5.7 13.0 8.6 2.9 5.1
(g/day) (20.0) (30.3) (20.0) (24.6) (25.7) (17.6) (22.9)
0.1250 0.5364 0.1171 0.3412 0.0029 0.6436
Alcohol .
that 20 g(f) or 40 g(m)/day or past abuse
23.4 32.7 20.4 29.0 25.5 20.1 21.6
(%) 0.3790 0.1787 0.2973 0.8885 0.0049 0.5775
Current or ex-smoking 56.2 64.5 47.9 50.7 58.5 58.1 54.1
(%) 0.0938 0.0062 0.3665 0.6453 0.5896 0.7125
Physically active during leisure time 58.2 45.8 49.5 53.6 48.1 36.2 52.7
(%) 0.0124 0.0043 0.4534 0.0423 ,.0001 0.3511
Data is expressed as Median (IQ-range 25–75) and p-value or % and p-value respectively.
Multinomial unadjusted logistic regression analyses and Mann-Whitney-Wilcoxon were used for bivariable comparisons with NGT as reference.
NGT: normal glucose tolerance, IFG: impaired fasting glucose, NFG: normal fasting glucose, IGT: impaired glucose tolerance, NDD: newly diagnosed diabetes, GGT:
gamma-glutamyltransferase, GOT: glutamate-oxalacetate transaminase, GPT: glutamate-pyruvate transaminase, AP: alkaline phosphatase, FLI: Fatty Liver Index, BMI:
Body Mass Index, HDL: high density lipoprotein, TC: total cholesterol, HbA1c: glycated hemoglobin, CRP: C-reactive protein.
doi:10.1371/journal.pone.0022932.t001
Table 1. Cont.
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Depending on the definitions described above, we got different
estimates of fatty liver frequency in our study sample (Table 3).
Applying the definition with reference values, 7.1% of the
participants had fatty liver disease (NAFLD or AFLD) (6.9% women,
7.3% men). Using the quartile definition, the numbers increased to
22.6% overall and 22.4 in women, 22.8% in men respectively. Using
the Bedogni Index even higher numbers resulted: there was a total of
39.8% fatty liver cases, 27.3% women and 53.2% men. The
percentages slightly increased in women (28.2%) and decreased in
men (51.3%) when subjects with significant alcohol consume were
omitted from the calculations, indicating that the number of
participants with alcoholic fatty liver disease was small.
Models featuring fatty liver as the main independent variable,
defined as two out of three liver enzymes above the upper reference
value (disregarding AP as the least influential parameter in our
study), yielded highly significant ORs of 2 to 4 in IFG, IGT, NDD
and known diabetes, but not in IFG/IGT, which was probably due
to very small case numbers in this group. These results remained
significant in most subgroups after controlling for confounding
variables. Similar numbers were obtained when fatty liver was
defined as two out of three enzymes above the upper 75% quartile.
Using the Bedogni Index as an estimation of fatty liver, all
persons with pre-diabetes and diabetes were significantly more
often affected than the NGT group with a 2 to 8 fold increase of
ORs, especially in NDD (OR 8.48, 95% CI: 5.13–14.00) and
IFG/IGT (OR 6.70, 95% CI: 3.74–12.01). These numbers even
increased slightly after exclusion of subjects with at-risk alcohol
intake (data not shown) and remained significant when confound-
ing variables were added to the models.
Interaction terms with fatty liver and sex controlled for age
where not significant in models with fatty liver definitions A and B,
but in the group with known diabetes using definition C
(p=0.0048). In models including age male participants with fatty
liver as defined by the FLI had an OR of 3.21 [95% CI 2.11–4.88]
for diabetes, female participants had an OR of 7.92 [95% CI
4.90–12.80]. In fully controlled models the ORs decreased to 2.72
[95% CI 1.71–4.34] and 3.61 [95% CI 2.08–6.27] respectively
Table 2. Association of liver enzymes with glucose subgroups: Normal glucose tolerance NGT was used as reference, ORs are
expressed per 1-SD increment in biomarker concentration.
N=3009 IFG-NGT NFG-IGT IFG/IGT NDD Known Diabetes Unknown
n (reference NGT)=2115 (n=107) (n=309) (n=69) (n=106) (n=229) (n=74)
GGT
Age-sex- adjusted OR 1.79 1.77 1.71 1.74 1.76 1.69
[95% CI] [1.50–2.13] [1.50–2.10] [1.34–2.18] [1.42–2.13] [1.47–2.09] [1.35–2.13]
p-value ,.0001 ,.0001 ,.0001 ,.0001 ,.0001 ,.0001
Multivariable- adjusted OR 1.47 1.49 1.36 1.41 1.43 1.45
[95% CI] [1.23–1.77] [1.26–1.76] [0.99–1.86] [1.11–1.79] [1.19–1.73] [1.19–1.77]
p-value ,.0001 ,.0001 0.0606 0.0047 0.0002 0.0002
GOT
Age-sex- adjusted OR 1.39 1.34 1.25 1.40 1.18 1.03
[95% CI] [1.21–1.59] [1.19–1.50] [1.00–1.56] [1.22–1.61] [1.00–1.39] [0.77–1.40]
p-value ,.0001 ,.0001 0.0526 ,.0001 0.0518 0.8297
Multivariable- adjusted OR 1.25 1.22 1.07 1.27 1.01 1.01
[95% CI] [1.08–1.44] [1.09–1.37] [0.81–1.42] [1.10–1.47] [0.84–1.21] [0.76–1.36]
p-value 0.0025 0.0005 0.6197 0.0014 0.9094 0.9254
GPT
Age-sex- adjusted OR 1.60 1.46 1.62 1.77 1.51 1.01
[95% CI] [1.37–1.87] [1.29–1.66] [1.34–1.97] [1.52–2.06] [1.30–1.74] [0.75–1.36]
p-value ,.0001 ,.0001 ,.0001 ,.0001 ,.0001 0.9456
Multivariable- adjusted OR 1.33 1.27 1.32 1.51 1.24 0.96
[95% CI] [1.12–1.58] [1.12–1.45] [1.05–1.67] [1.27–1.79] [1.06–1.45] [0.71–1.30]
p-value 0.0009 0.0002 0.0186 ,.0001 0.0077 0.7847
AP
Age-sex-adjusted OR 1.41 1.18 1.07 1.23 1.11 1.00
[95% CI] [1.19–1.66] [1.05–1.34] [0.83–1.38] [1.01–1.48] [0.95–1.28] [0.78–1.28]
p-value ,.0001 0.0058 0.6122 0.0391 0.1900 0.9817
Multivariable- adjusted OR 1.26 1.03 0.89 0.98 0.89 0.91
(95% CI) [1.04–1.52] [0.90–1.17] [0.67–1.19] [0.79–1.23] [0.75–1.05] [0.70–1.19]
p-value 0.0161 0.6933 0.4252 0.8898 0.1556 0.5046
Multivariable-adjusted models included age, sex, education, BMI, hypertension, TC/HDL-cholesterol ratio, uric acid, CRP, alcohol intake, smoking status, and physical
activity.
doi:10.1371/journal.pone.0022932.t002
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more (0.0650).
Similarly to the single enzyme models, all Pseudo-R-Square
values were between 0.2 and 0.4 and all Pearson tests and AICs
showed appropriate goodness-of-fit.
Effect modification by BMI
In models stratified for BMI subgroups the association between
fatty liver on the one hand and diabetes or pre-diabetes on the other
hand was most pronounced in slim men (Def. A, multivariable
adjusted OR=4.94, 95% CI 1.17–20.89, sex*FLI interaction:
p=0.0434, not shown in the table), and pre-obese men and women
with significant ORs of around 2 to 7 inage-sex adjusted modelsand
2 to 5 in multivariable-adjusted models, see table 4. The interaction
term sex*FLI was only significant in the group with normal weight
using definition A. The effects were smaller, though still significant
(except for Def. C mutlivariable adjustment) in the obese group.
Interaction by BMI was p,0.0001 in all fatty liver definitions.
Table 3. Association of fatty liver with glucose tolerance subgroups: Normal glucose tolerance was used as reference, fatty liver
was defined in three different ways (A–C) as specified in the table.
N=3009 IFG-NGT NFG-IGT IFG/IGT NDD Known Diabetes Unknown
n(NGT)=2115 (n=107) (n=309) (n=69) (n=106) (n=229) (n=74)
A: Definition of fatty liver: two or three out of three enzymes (GGT, GOT and GPT) above upper reference value
N (fatty liver, all participants)=213 (7.1%)
N (fatty liver, reference NGT)=106 (5.0%)
N (fatty liver) 14 34 6 16 30 7
(%) (13.1) (11.0) (8.7) (15.1) (13.1) (9.5)
Age-sex- adjusted OR 3.38 2.83 2.29 4.42 4.08 2.05
(95% CI) [1.84–6.21] [1.85–4.33] [0.96–5.50] [2.45–7.97] [2.55–6.52] [0.92–4.59]
p-value ,.0001 ,.0001 0.0628 ,.0001 ,.0001 0.0806
Multivariable-adjusted OR 2.10 2.11 1.34 2.63 2.64 1.91
(95% CI) [1.11–3.97] [1.36–3.27] [0.54–3.31] [1.40–4.94] [1.60–4.35] [0.84–4.35]
p-value 0.0231 0.0009 0.5305 0.0027 0.0001 0.1234
B: Definition of fatty liver: two or three out of three enzymes above 75% quartiles of the population
N (fatty liver, all participants)=680 (22.6%)
N (fatty liver, reference NGT)=395 (18.7%)
N (fatty liver) 37 102 23 45 59 19
(%) (34.6) (33.0) (33.3) (42.5) (25.8) (25.7)
Age-sex- adjusted OR 2.50 2.29 2.49 3.77 1.87 1.50
(95% CI) [1.64–3.82] [1.74–3.01] [1.47–4.21] [2.48–5.73] [1.34–2.62] [0.88–2.55]
p-value ,.0001 ,.0001 0.0007 ,.0001 0.0003 0.1386
Multivariable- adjusted OR 1.67 1.79 1.53 2.50 1.30 1.41
(95% CI) [1.07–2.61] [1.34–2.38] [0.88–2.65] [1.60–3.91] [0.91–1.86] [0.81–2.45]
p-value 0.0246 ,.0001 0.1321 ,.0001 0.1558 0.2227
C: Definition of fatty liver: according to Fatty Liver Index (Bedogni, 2006)
N (fatty liver, all participants)=1198 (39.8%)
N (fatty liver, reference NGT)=611 (28.9%)
N (fatty liver) 77 180 53 85 161 31
(%) (72.0) (58.2) (76.8) (80.2) (70.3) (41.9)
Age-sex adjusted OR 4.96 3.14 6.70 8.48 4.78 1.60
(95% CI) [3.17–7.75] [2.42–4.08] [3.74–12.01] [5.13–14.00] [3.47–6.59] [0.98–2.62]
p-value ,.0001 ,.0001 ,.0001 ,.0001 ,.0001 0.0605
Multivariable- adjusted OR 2.98 2.45 3.66 4.96 3.09 1.30
(95% CI) [1.82–4.87] [1.83–3.28] [1.95–6.86] [2.86–8.60] [2.17–4.40] [0.75–2.27]
p-value ,.0001 ,.0001 ,.0001 ,.0001 ,.0001 0.3521
Multivariable-adjusted models included age, sex, education, BMI, hypertension, TC/HDL-cholesterol ratio, uric acid, CRP, alcohol intake, smoking status, and physical
activity – BMI was not included in C because it was used to calculate the index.
doi:10.1371/journal.pone.0022932.t003
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In order to rule out effect modification from medication use, we
conducted a sensitivity analysis calculating models stratified for
medication intake and combined probands with diabetes and pre-
diabetes to increase statistical power. Participants with pre-diabetes
or diabetes were 2.38 times (95% CI 1.90–2.99, p=,.0001) more
likely to take any prescription medication. Thus, the subgroup using
no medication consisted of 104 (15.6%) probands with diabetes or
pre-diabetes and 563 (84.4%) healthy probands. The subgroup
using medication included 716 (30.57%) probands with diabetes or
pre-diabetes and 1626 (69.43%) healthy probands.
In persons taking no medication, the age and sex adjusted
regression effect of fatty liver disease (definition C, Bedogni Index)
on glucose disorder had an OR of 5.77 (95% CI 3.40–9.55,
p=,0.0001), in persons using medication the respective OR was
4.06 (95% CI 3.30–5.00, p=,0.0001). In multivariable adjusted
models, we found ORs 4.29 (95% CI 2.43–7.58, p=,0.0001) and
2.71 (95% CI 2.14–3.44, p=,0.0001) respectively.
P-Interaction by medication use was not significant using any
fatty liver definition.
Discussion
GGT and GPT were significantly elevated in persons with pre-
diabetes and diabetes in our study, GOT and AP only in some
groups. The effects were sharpened in models using an increase of
two out of three enzymes as an estimate of fatty liver and especially
in models using the Fatty Liver Index by Bedogni et al.. Up to
eight times more KORA participants with fatty liver disease had
pre-diabetes or diabetes compared to the healthy reference group.
Table 4. Frequencies and association of fatty liver and glucose metabolism disturbance (pre-diabetes or diabetes) within BMI
subgroups.
BMI Group
,25 kg/m
2
Under (n=10) and Normal weight
25 – ,30 kg/m
2
Pre-Obesity
$30 kg/m
2
Obesity I, II, III
n=953 n=1255 n=801
N (%) with Fatty liver
Def. A 33 (3.5) 76 (6.1) 104 (13.0)
Def. B 122 (12.8) 282 (22.5) 276 (34.5)
Def. C 26 (2.7) 460 (36.7) 712 (88.9)
N (%) with
Diabetes 23 (2.4) 82 (6.5) 124 (15.5)
Pre-diabetes 80 (8.4) 237 (18.9) 274 (34.2)
both 103 (10.8) 319 (25.4) 398 (49.7)
Def. A
Age-sex- adjusted OR 2.09 3.51 1.90
(95% CI) 0.79–5.54 2.07–5.95 1.21–2.98
p-value 0.1387 ,0.0001 0.0054
Def. A
Multivariable-adjusted OR 1.92 3.14 1.62
(95% CI) 0.71–5.21 1.81–5.42 1.02–2.58
p-value 0.2000 ,0.0001 0.0427
Def. B
Age-sex- adjusted OR 2.26 2.13 1.51
(95% CI) 1.30–3.93 1.56–2.93 1.10–2.07
p-value 0.0039 ,0.0001 0.0108
Def. B
Multivariable-adjusted OR 2.13 1.90 1.34
(95% CI) 1.20–3.77 1.37–2.64 0.97–1.87
p-value 0.0099 0.0001 0.0798
Def. C
Age-sex- adjusted OR 7.48 2.70 1.85
(95% CI) 2.92–19.18 1.99–3.67 1.10–3.12
p-value ,0.0001 ,0.0001 0.0212
Def. C
Multivariable-adjusted OR 5.45 2.28 1.20
(95% CI) 2.00–14.85 1.63–3.19 0.68–2.12
p-value 0.0009 ,0.0001 0.5239
Multivariable-adjusted models included age, sex, education, hypertension, TC/HDL-cholesterol ratio, uric acid, CRP, alcohol intake, smoking status, and physical activity.
doi:10.1371/journal.pone.0022932.t004
I-M. Ru ¨ckert et al.: Fatty Liver and Pre-Diabetes
PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e22932Sensitivity analyses excluding participants with very high liver
enzyme values still yielded significant associations of impaired
glucose tolerance and liver enzyme concentrations as did models
that included a variety of known confounding variables. Likewise,
the exclusion of alcohol drinkers did not diminish the effects. We
found that particularly in slim men and pre-obese men and
women fatty liver disease posed a significant risk for pre-diabetes
and diabetes. This supports the idea that fatty liver is a risk factor
independent of BMI even though it is more frequent in overweight
people. Finally, medication intake diminished the association of
NAFLD and glucose metabolism disorder, probably because of a
beneficial effect of diabetes medication on the fatty liver, which is
able to recover in early stages.
The liver occupies a sentinel position between the alimentary
canal and the systemic circulatory system and has wide exposure
to toxins and drug metabolites, endotoxins, and infectious agents.
Consequently, a wide spectrum of nonhepatic disorders may
influence liver enzyme activity. The pattern of liver enzyme
abnormalities only provides a first indication of a liver-specific
disease [4,31]. For lack of specific diagnoses of liver disorders in
our study we could not exclude patients affected with other liver
diseases. Defining elevated liver enzymes as fatty liver disease we
found very consistent associations with impaired glucose tolerance
and diabetes, even after exclusion of individuals with liver values
above certain reference thresholds. These findings match very well
with similar analyses in recent literature [8,9,12–16,32–35] and
confirm the fact that the liver is closely involved in glucose
metabolism and plays an important role in the development of
metabolic disorders.
An earlier evaluation of a different subsample of the MONICA/
KORA study [33] already demonstrated a clear correlation of
GGT with incident diabetes that was stronger in men than in
women. After multivariable adjustment hazard ratios of 1.81
($50
th vs. ,25
th percentile) to 4.24 ($87.5
th vs. ,25
th percentile)
across GGT categories were found in men and 1.42 to 2.41 in
women respectively over a follow up period of 14.7 years. Our new
analysis also took into account further relevant liver enzymes and
pre-diabetic states.
The prospective Japanese Hisayama Study found that the age-
adjusted cumulative incidence of diabetes increased significantly
from lower to higher quartiles of GGT and GPT. The association
remained significant after controlling for comprehensive risk
factors in both sexes. GOT results were not that clear [32].
Similarly, data from the British Women’s Health and Heart Study
revealed associations between GGT and GPT with fasting glucose,
fasting insulin and HbA1c as measures of glucose homeostasis in
3086 without and 308 women with diabetes. Interestingly, these
associations did not differ substantially between obese and non-
obese non-diabetic women. The authors cite that liver fat content
is not stringently correlated with intra-abdominal or subcutaneous
fat depots, thus explaining that non-obese individuals may
occasionally be more affected by fatty liver and interrelated
metabolic impairments than obese individuals [12]. An analysis
using data from the Framingham Heart Study also confirmed that
fatty liver is associated with dysglycemia independent of visceral
adipose tissue and other obesity measures [35].
In a meta-analysis with participants of the British Women’s
Health and Heart Study, the research group confirmed their first
findings, and added ultrasound examinations of the liver.
Ultrasonography-diagnosed NAFLD was associated with a
doubling in the risk of incident diabetes and both GGT and
GPT predicted diabetes. [8]
Hanley et al. used data from the Insulin Resistance Atheroscle-
rosis Study conducted in the US and described positive
associations of GOT and GPT with incident type 2 diabetes,
fasting insulin, waist circumference and fasting glucose, concluding
that GOT and GPT independently predict type 2 diabetes [9].
All four potentially relevant liver enzymes were studied in the
population-based Mexico City Diabetes Study involving 1,441
men and women in whom serum enzyme levels were #3 SDs of
the mean population value. At the 7 years follow-up 94 subjects
had developed diabetes and 93 impaired glucose tolerance. Upon
including known confounding factors, GPT and GGT values were
significantly associated with both IGT and diabetes, AP with
diabetes only and GOT with IGT only. Raised GGT alone was
associated with all the features of the metabolic syndrome. The
authors concluded that raised GGT is an independent predictor of
deterioration of glucose tolerance to IGT or diabetes and may
reflect hepatic steatosis and oxidative stress [13].
Mohan et al. investigated the relationship in urban south Indian
subjects, applying OGT test and ultrasonography of the liver and
concluded that NAFLD was present in a third of the included
subjects and increased significantly with increasing severity of
glucose tolerance (NGT: 22.5%, IFG: 27.3%, IGT: 32.4%, IGT/
IFG: 33.0%, type 2 diabetes: 54.5%) [34]. These numbers go
rather well together with our quartile definition, but we did not
find such a perfect continuous rise in frequency (NGT: 18.7%,
IFG: 34.6%, IGT: 33.0%, IGT/IFG: 33.3%, NDD: 42.5%,
known diabetes: 25.8%).
The theory has been raised that analogous to Palmipedes
(migratory fowl) fatty liver could be a natural adaptation to
facilitate survival in a cold and resource-scarce environment. This
would explain why fatty liver is not a uniform feature of the
metabolic syndrome but varies remarkably within ethnicities and
individuals [36] and why obese individuals displaying the
metabolically healthy but obese (MHO) phenotype present
favourable levels of liver enzymes [37].
To put it into a nutshell, the results of the population-based
KORA study are not completely novel, but nevertheless make a
valuable contribution to the present body of acquired knowledge.
The Fatty Liver Index has not been used exhaustively in the past.
However, we found that the FLI is a useful approximation in a
population-based study that cannot collect biopsy data due to
ethical concerns. The Fatty Liver Index has also been used in the
French D.E.S.I.R Study in association with incident diabetes [18].
The authors found that a FLI $70 in comparison with a FLI ,20
had an age adjusted OR of 9.33 (95% CI 5.05–17.25) for men and
36.72 (95% CI 17.12–78.76) for women. They concluded that the
FLI is predictive of diabetes in men and women independently of
traditional risk factors and suggested that the index should be used
by hepatologists to better identify patients at high risk of diabetes.
Similarly, in the Italian RISC study a significant reduction of
insulin sensitivity was found in middle-aged non-diabetic subjects
with a FLI Score greater than or equal 60 [19].
Our study shows, that even though liver values are differently
distributed in men and women, the risk of elevated enzymes on
metabolic disorders is equally present in both sexes. BMI is
strongly associated with NAFLD, however, the negative influence
of NAFLD on glucose metabolism (or vice versa) is definitely
detectable in slender and pre-obese individuals.
Study limitations
In the population based KORA study only liver enzyme
measurements as surrogates of fatty liver disease were accessible,
ultrasounds could unfortunately not be implemented and biopsies
can not be done in epidemiological studies in mostly healthy
subjects. It has been stated that by using liver enzymes alone the
true prevalence of NAFLD may be underestimated by more than
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diagnosed with NAFLD actually present normal aminotransferase
levels [2]. 20% of young patients with non-alcoholic steatohepatitis
(NASH) and/or fibrosis diagnosed by biopsies and histological
examinations also have normal GPT values at the time of biopsy
[38]. By using the Bedogni-Index in addition to the liver enzymes,
we tried to improve our assessment of NAFLD cases and found
that the association between the index and pre-diabetes or diabetes
respectively was remarkably stronger than for the liver enzymes
alone.
We did not omit participants with significant consumption of
alcohol from our main models and therefore cannot exclude, that
some cases of fatty liver were due to alcohol abuse, but sensitivity
analyses without the participants in question showed consistent
results. Unfortunately, verified information on viral hepatitis status
that could have affected liver enzymes was not available in the
present study.
Moreover, we only looked at cross sectional data of the KORA
study and are thus not able to give evidence for temporal causality
of the associations described above.
In conclusion elevated GGT and GPT – values as well as
estimates of fatty liver disease are significantly associated with pre-
diabetes and diabetes and thus easily available and relatively
inexpensive first indicators of a disturbed glucose metabolism.
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